Actively Recruiting

Phase 4
Age: 2Months - 18Years
All Genders
ID06982105

Comparing Trimethoprim-Sulfamethoxazole and Clindamycin for Treating Children with Invasive MRSA Infections

Led by Indiana University · Updated on 2025-06-04

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating how well trimethoprim-sulfamethoxazole (TMP-SMX) works compared to clindamycin in treating invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in children. The study also aims to understand the safety of TMP-SMX when used for these infections. This is a Phase 4 clinical trial involving children with confirmed or suspected MRSA infections affecting bones, joints, or head and neck areas. Participants will be randomly assigned to receive either TMP-SMX or clindamycin as oral antibiotic therapy. The dosing for TMP-SMX varies depending on the infection type: 4-5 mg/kg every 8 hours for osteoarticular infections or 5-6 mg/kg every 12 hours for head and neck infections, with maximum doses specified. Clindamycin is given at 13 mg/kg every 8 hours. Treatment duration is determined by the healthcare provider. The study compares these two treatments to see which works better or if they are similar. During the trial, children will take the assigned antibiotic and keep a diary to track symptoms and any side effects. Follow-up visits will occur as decided by their healthcare provider. Researchers will measure treatment success six weeks and six months after hospitalization and monitor any antibiotic-related side effects. Participation lasts through these follow-up periods to ensure careful assessment of outcomes and safety.

CONDITIONS

Brief Title

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

Who Can Participate

Age: 2Months - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 60 days and 18 years at the time of oral antibiotic treatment
  • Diagnosed with osteoarticular infection (OAI) or head and neck infection (HNI) confirmed by clinical findings or imaging
  • Confirmed or suspected MRSA infection treated by the clinical team
  • Ready or planned to start oral antibiotic therapy
  • Symptoms of OAI or HNI less than 14 days at hospital admission
Not Eligible

You will not qualify if you...

  • Enrolled in another interventional study or received investigational drug in past 30 days
  • Known cancer or immunodeficiency including sickle cell anemia or G6PD deficiency
  • Underlying bone disease or implantable device in affected bone or joint
  • Infection resulting from penetrating wounds, fractures, trauma, foreign body, or post-operative infection
  • Spinal osteomyelitis
  • Chronic renal, gastrointestinal, liver, or heart disease affecting drug absorption or metabolism
  • Unable to take medicine by mouth or feeding tube
  • Received intravenous antibiotics for OAI or HNI for more than 14 days
  • Unable or unwilling to consent
  • Social or medical conditions that may affect participation
  • Allergy to both TMP-SMX and clindamycin
  • Known MRSA resistant to both TMP-SMX and clindamycin
  • Known pregnancy at enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - At the discretion of the treating provider

Participants receive oral antibiotic treatment with either trimethoprim-sulfamethoxazole or clindamycin as prescribed by their provider.

Visits as scheduled by the clinical team during treatment

Follow-up

Duration - Up to 6 months post hospitalization

Participants are monitored for treatment success and antibiotic-related adverse events after completing treatment.

Follow-up visits at 6 weeks and 6 months post hospitalization

Trial Site Locations

Total: 1 location

1

Riley Hospital for Children

Indianapolis, Indiana, United States, 46202

Actively Recruiting

Loading map...

Research Team

M

Mary Stumpf

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Alpha-Defensin and Synovial Proteins to Improve Detection of...

Joint Infection

Actively Recruiting

3 locations

BonE and Joint Infections - Simplifying Treatment in Childre...

Bone Infection

Actively Recruiting

10 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here